Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(4):254-255; doi:10.1093/jnci/93.4.254
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Johnson, B. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, B. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 4, 254-255, February 21, 2001
© 2001 Oxford University Press

EDITORIAL

Is More Better? Chemotherapy for Patients With Extensive-Stage Small-Cell Lung Cancer

Bruce E. Johnson

Affiliations of author: Lowe Center for Thoracic Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

Correspondence to: Bruce E. Johnson, M.D., Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Rm. D1234, 44 Binney St., Boston, MA 02115 (e-mail: BEJohnson@partners.org).

More is usually better for most of the things that we utilize or consume in our lives. In this issue of the Journal, Pujol et al. (1) report on a study in which they attempted to answer the question of whether more chemotherapy is better for patients with extensivestage small-cell lung cancer. The answer from their study design in this patient population is that more chemotherapy is better. In their introduction and discussion, Pujol et al. carefully document that most previous approaches for giving more chemotherapy to patients with extensive small-cell lung cancer have not increased survival. Should their four-drug regimen, which does appear to prolong survival, now be adopted as the new standard treatment for extensive-stage small-cell lung cancer, or is further clinical research needed? I will comment on the toxicity of their four-drug regimen and on the survival of the patients treated on this and other . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?